Oncorus to Present at Upcoming Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Oncorus, focused on viral immunotherapies for cancer, announced that its CEO, Theodore (Ted) Ashburn, M.D., Ph.D., will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:00 p.m. ET. A live webcast of the presentation will be accessible via the Investors & Media section on their website, with a replay available for 30 days post-event. Oncorus is developing innovative treatments using their oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform, aiming to enhance therapeutic potency while minimizing systemic toxicity.

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will present at the upcoming Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:00 p.m. ET.

A live webcast of the presentation will be available under the Investors & Media section of Oncorus’ website at https://investors.oncorus.com/events-and-presentations. A replay of the presentation will be archived on Oncorus’ site for 30 days following the event.

About Oncorus

At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients. We are advancing a portfolio of intratumorally and intravenously administered viral immunotherapies for multiple indications with significant unmet needs based on our oncolytic Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform. Designed to deliver next-generation viral immunotherapy impact, our oHSV platform improves upon key characteristics of this therapeutic class to enhance potency without sacrificing safety, including greater capacity to encode transgenes to drive systemic immunostimulatory activity, retention of full replication competency to enable high tumor-killing potency, and orthogonal safety strategies to restrict viral activity in tumor cells. Our lead oHSV program, ONCR-177, is designed to be directly administered into a tumor, resulting in high local concentrations of the therapeutic agent, as well as low systemic exposure to the therapy, which we believe could potentially limit systemic toxicities. Please visit www.oncorus.com to learn more.

Media Contact:
Liz Melone
liz@scientpr.com
617-256-6622

FAQ

When will Oncorus present at the Jefferies Virtual Healthcare Conference?

Oncorus will present on June 2, 2021, at 2:00 p.m. ET.

Where can I watch the Oncorus presentation?

The presentation will be available as a live webcast on Oncorus' website under the Investors & Media section.

What is the focus of Oncorus?

Oncorus focuses on developing viral immunotherapies aimed at transforming cancer treatment outcomes.

What platform does Oncorus use for its immunotherapies?

Oncorus employs the oncolytic Herpes Simplex Virus (oHSV) Platform and the Synthetic Virus Platform.

What is ONCR-177?

ONCR-177 is Oncorus' lead oHSV program designed for intratumoral administration, targeting high local concentrations while minimizing systemic exposure.